Table 1.
Intermediate PAWS workshop topics from 1999–2019
| Year | Workshop title | Workshop description |
|---|---|---|
| 2019 | PAWS at the joint ASCEPT‐PAGANZ 2019 meeting | Nlmixr workshop |
| TMDD | Target‐mediated drug disposition model, modeling, and applications in drug development | |
| CellML | Model definition using the mark‐up language CellML | |
| OpenCOR | Framework for simulation using CellML | |
| 2018 | STAN | Model estimation and Bayesian inference using Stan |
| DDMoRe | Overview of the Drug Disease Model Resources (DDMoRe) project | |
| 2017 | R and Shiny | Model building and evaluation using R and Shiny apps |
| Receptor theory | Introduction to multistate receptor theory and biased ligands | |
| 2016 | No PAGANZ meeting | PAGANZ Inc. hosted WCoP2016 (www.wcop2016.org) |
| 2015 | PBPK | Physiologically‐based pharmacokinetic model definition, estimation, and evaluation using Berkeley Madonna |
| TTE | Time‐to‐event model development and evaluation | |
| 2014 | Phoenix | Model definition, estimation, and evaluation using Phoenix NLME |
| QT interval | Population PKPD modelling of the QT interval using Phoenix NLME and NM‐TRAN | |
| Lifespan models | An introduction to lifespan‐based indirect drug response models | |
| 2013 | Optimal design | Application of population optimal design in drug development, preclinical and clinical trials |
| Categorical data | Development and evaluation of population models of categorical data | |
| 2012 | Transformation | Transformation of parameter and residual error distributions |
| Trial Simulator | Clinical trial and adaptive simulation | |
| Anti‐infectives | Population PKPD modelling of antibiotics including bacterial growth, resistance, and killing | |
| 2011 | Missing data | Modeling of left‐censored PK data and missing covariates |
| Biological systems | Large‐system simulation using the CellML mark‐up language | |
| Optimal design | Model discrimination using optimal design and introduction to DT optimality | |
| 2010 | VPC | The use and interpretation of visual predictive check plots in model evaluation |
| Monolix | Population PKPD modelling using Monolix and NONMEM | |
| 2009 | WinBUGS | Introduction to Bayesian statistics and WinBUGS |
| TTE | Time‐to‐event model development and evaluation using NONMEM and WinBUGS | |
| 2008 | Model Diagnostics | Empirical Bayes estimates, shrinkage, and residual error using PsN and Xpose for model diagnosis |
| Nonparametric | Semiparametric and nonparametric estimation in NONMEM VI | |
| 2007 | Monolix | An introduction to population PKPD modelling using Monolix |
| TTE | Time‐to‐event model development and evaluation | |
| 2006 | Discrete Data | Modelling non‐continuous data in NONMEM |
| Pediatrics | PKPD model development in pediatrics | |
| Optimal Design | Optimal design in drug development and postmarketing clinical trials | |
| 2005 | PD | Introduction to immediate effect models, effect compartment, and turnover models |
| PKPD | Simultaneous vs. sequential PKPD modelling | |
| 2004 | NONMEM | The use of “advanced” features of NONMEM including OMEGA blocks and baseline effect parameter |
| 2003 | NONMEM | The use of “advanced” features of NONMEM including logistic regression, differential equations, and bootstrapping |
| 2002 | PAGANZA | Meeting in South Africa |
| 2002 | CTS | Introduction to clinical trial simulation including design and simulation plans |
| Pharmacoeconomic models | Introduction to pharmacoeconomic models | |
| 2001 | Bayesian statistics | Introduction to Bayesian statistics and PKBUGS. Also, FOCE, EBEs, and the PRIOR subroutine in NONMEM |
| 2000 | PK and PKPD | Introduction to population PK and PKPD model development |
| 1999 | No PAWS at the first meeting | – |
ASCEPT, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists; CTS, clinical trial design; DT, optimality criteria; EBEs, empirical Bayes estimates; FOCE, first order conditional estimation; NLME, nonlinear mixed effects; PAWS, Population Analysis Workshop; PBPK, physiologically‐based pharmacokinetic; PD, pharmacodynamic; PK, pharmacokinetic; TMDD, target‐mediated drug disposition; VPC, visual predictive checks; WCoP2016, World Conference of Pharmacometrics 2016.